# KPV peptide dosage in research: in-vitro, oral, and topical concentrations | KPV Store > KPV peptide dosage as studied in research: ~10 nM in cells, ~100 uM in mouse drinking water, 1-10 mg/mL topical eye drops in rabbits. No validated human dose exists. Routes, frequency, and stability, cited. KPV peptide dosage outside of research has never been validated. Here is exactly what was administered, to which species, by which route — described as research context, never as guidance. ## Before the details A clear warning up front: there is no established human dose of KPV, and nothing on this page is a protocol or a recommendation. Everything below is a description of what scientists put into cell dishes and animals. KPV peptide dosage in the literature spans three very different settings — tiny amounts in cell culture, a concentration mixed into mouse drinking water, and eye drops in rabbits. Because KPV is fragile and broken down quickly by the body, much of the newer work is really about packaging it to survive, not about a "dose" in the everyday sense. ## KPV Peptide Dosage in the Research Literature KPV peptide dosage in the research literature falls into three model-specific buckets, none of which translates to a human amount [13]. In cell culture, the active anti-inflammatory concentration was about 10 nanomolar (nM) in intestinal-epithelial and immune cells, with some other cell systems using up to low-micromolar levels (roughly 0.1-10 micromolar) [1][6]. In live animals, mouse colitis studies delivered about 100 micromolar (uM) KPV dissolved in the animals' drinking water [1]. In the rabbit corneal study, drops were dosed at 1, 5, or 10 mg/mL, four times daily [6]. These figures are not comparable to one another, let alone to a hypothetical human dose: a culture-dish concentration, a drinking-water concentration, and a topical drop concentration measure different things. The literature reports no established or validated human research dose [13]. ## Research Doses and Routes Used for KPV The routes studied for KPV are mostly oral and topical rather than injection [13]. In gut models, KPV was given orally — in drinking water, or encapsulated in nanoparticles and hydrogels delivered by gavage [1][5]. In eye studies it was topical, as drops [6]. Wound studies used topical mucoadhesive and film dressings [8][9]. Select inflammation models of the broader peptide family used intraperitoneal delivery [3]. The doses, restated as the studies recorded them: about 10 nM in vitro (up to low-micromolar in some cell systems) [1][6]; about 100 uM in mouse drinking water [1]; and 1-10 mg/mL topical eye drops in rabbits [6]. Each is a research-context figure tied to a specific model, with no human equivalent [13]. ## What Doses of KPV Have Been Studied? Research doses span roughly 10 nM in intestinal-epithelial and immune cells (up to low-micromolar in other systems), about 100 uM in drinking water in mouse colitis, and 1-10 mg/mL topical eye drops in rabbits [1][6]. There is no established human dose of KPV, because no human clinical trials have been published [13]. ## Routes and Frequency Used for KPV in Research Most KPV research uses oral routes (drinking water, or nanoparticle/hydrogel-encapsulated by gavage) and topical routes rather than injection [1][5][6]. There is no validated human injection frequency; reported frequencies are model-specific — for example, four-times-daily topical drops in the corneal study [6] and continuous delivery in drinking water in colitis models [1]. ## Was KPV Administered Daily in Research? Yes, animal protocols used repeated or daily administration. Colitis models delivered KPV continuously in drinking water, and the corneal study dosed four times daily for four days [1][6]. No validated human frequency exists, because KPV has not been studied in human trials [13]. ## Duration of KPV Use in Research Durations are defined only by individual animal models and run from days to weeks. The rabbit corneal study ran four days [6]; colitis models ran over the course of the induced disease [1]. There is no validated human course length for KPV, because no human clinical trials have been published [13]. ## Half-Life and Stability: Why Formulation Dominates As a small, unprotected tripeptide, KPV is expected to be degraded rapidly by peptidases, and no validated human pharmacokinetic half-life has been published [13]. Free KPV is susceptible to enzymatic breakdown in both the gastrointestinal tract and serum [13]. This single fact shapes the whole modern literature: the bulk of 2016-2026 research develops hyaluronic-acid nanoparticles, polysaccharide and double-network hydrogels, and self-assembled carrier-free nanodrugs to stabilize KPV and target it to inflamed tissue, often via PepT1 [13]. A 2024 study even self-assembled KPV with rapamycin into carrier-free nanodrugs for a vascular-calcification model, illustrating newer co-assembly delivery chemistry [14]. In short, for KPV the delivery system is often the real experiment. --- A friendly reading shelf of the KPV peptide literature — the in-vitro and mouse findings on this alpha-MSH tripeptide laid out gently, the absent human trials left honestly blank, and its FDA-evaluation standing noted before anything else; nothing here is a clinic, a prescription, or for sale.